You might also like
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company specializing in the development of chimeric antigen receptor cell therapy (CAR-T) for light chain (AL) Amyloidosis and select immune-mediated diseases. The company is focused on advancing its lead candidate, NXC-201, through clinical trials and obtaining regulatory approvals. Immix Biopharma does not currently sell any approved products, as it is still in the clinical-stage of development.
- CAR-T NXC-201 - FDA investigational new drug (IND) cleared cell therapy candidate being evaluated in clinical trials for relapsed/refractory AL Amyloidosis and select immune-mediated diseases. Awarded Orphan Drug Designation by the FDA and European Commission for AL Amyloidosis.
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Gabriel Morris ExecutiveBoard | Chief Financial Officer | Managing Partner at Alwaysraise LLC | Gabriel Morris has served as Chief Financial Officer and Director of Immix Biopharma, Inc. since March 2021. He is also the sole member and Managing Partner of Alwaysraise LLC, contributing his extensive financial expertise. | |
Ilya Rachman ExecutiveBoard | Chief Executive Officer (CEO) and Chairman of the Board of Directors | Ilya Rachman, MD, PhD, MBA is the founder, Chairman, and Chief Executive Officer of Immix Biopharma, Inc. since 2012. He is a pioneering physician/scientist and cell biologist with extensive experience in clinical research and prominent healthcare institutions. | View Report → | |
Carey Ng Board | Member of the Board of Directors | Managing Director at Mesa Verde Venture Partners; Member of the Investment Committee | Carey Ng has been serving as a Board Director at IMMX since November 2019 and is a member of the Audit Committee. He brings over fifteen years of experience in the biomedical industry and holds a Ph.D. from UCLA and an MBA from UC San Diego. | |
Helen C. Adams Board | Member of the Board of Directors and Audit Committee Chair | Partner Emeritus at Haskell & White LLP | Helen C. Adams has served as a board member and Audit Committee Chair at IMMX since June 2021, and she brings extensive experience in public accounting and the life sciences industry from her roles at Deloitte, Haskell & White LLP, and Prometheus Biosciences. | |
Jane Buchan Board | Member of the Board of Directors | CEO of Martlet Asset Management; Board Member of AGF Management Ltd; Chairwoman of CAIA; Advisory Board Member at UCLA Anderson School of Management; Trustee at Reed College and University of California Irvine Foundation | Jane Buchan has been a member of the Board of Directors at IMMX since June 2021, bringing extensive experience from her prior roles as CEO of PAAMCO and Martlet Asset Management, as well as significant contributions in academia and governance. | |
Jason Hsu Board | Director | Founder, Chairman, and Chief Executive Officer at Rayliant Global Advisors; Chief Economist at East West Bank | Jason Hsu has served as Director and independent member of the Board of Directors at IMMX since 2013. He brings extensive expertise in finance and investment strategies to his role. | |
Magda Marquet Board | Member of the Board of Directors | Member of the Board of Directors at AnaptysBio, Inc.; Member of the Board of Directors at Arcturus Therapeutics; Member of the Board of Directors at Transcode Therapeutics; Chair of the Board at Matrisys Bioscience; Co‐CEO of Alma Life Sciences LLC; Co-Founder of AltheaDx | Magda Marquet has served as a board member of Immix Biopharma, Inc. since June 2021 and is the chair of its Compensation Committee as well as a member of the Nominating and Corporate Governance Committee. She brings extensive biopharmaceutical experience from multiple leadership roles. | |
Yekaterina Chudnovsky Board | Member of the Board of Directors | General Counsel for an International Privately-Held Technology Firm (2009); Chairperson/President of GI Research Foundation (2012/2019); Board Member of XCures; Board Member of Elicio Therapeutics, Inc. (October 2022); Managing Director of GKCC, LLC | Yekaterina Chudnovsky has been a Board Member of Immix Biopharma, Inc. since August 2023 and serves as an independent director under SEC and Nasdaq regulations. She has also held roles as General Counsel for an international privately-held technology firm since 2009, Chairperson/President of the GI Research Foundation, and served on the boards of XCures and Elicio Therapeutics, Inc.. |
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
This company has publicly disclosed developing therapies for AL amyloidosis, which is a competitive area for the company's development programs. | |
This entity has publicly disclosed developing therapies for AL amyloidosis, presenting competition in the biotechnology industry. | |
This organization has publicly disclosed developing therapies for AL amyloidosis, competing in the same therapeutic area as the company. | |
This company has publicly disclosed developing or intending to develop cell therapies for immune-mediated disease indications, which overlaps with the company's focus. | |
This company has publicly disclosed developing or intending to develop cell therapies for immune-mediated disease indications, posing competition in this field. | |
This company has publicly disclosed developing or intending to develop cell therapies for immune-mediated disease indications, competing with the company's efforts. | |
This company has publicly disclosed developing or intending to develop cell therapies for immune-mediated disease indications, representing a competitive force in the industry. |
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
Nexcella, Inc. | 2024 | Acquired by Immix Biopharma, Inc. via a merger on May 20, 2024; under the deal structure, as part of the merger Nexcella’s outstanding shares (excluding those held by Immix) were converted into 989,876 shares of Immix common stock with additional equity awards issued through the Nexcella 2022 Equity Incentive Plan, effectively transferring all its assets, operations, and rights to Immix in a streamlined transaction. |
Recent press releases and 8-K filings for IMMX.
- Immix Biopharma, Inc. entered into an at-the-market offering agreement with Citizens JMP Securities on June 3, 2025 to offer and sell its common stock via an effective registration statement filed on January 3, 2023.
- Under the agreement, the company may sell shares subject to limits outlined by its registration statement, with a 3% commission on gross sales and reimbursement of certain expenses up to $50,000.